Sanofi Aventis – Global Innovations for Patient Health
Sanofi Aventis
Sanofi is a French pharmaceutical company headquartered in Paris. The present company took shape in 2004, when Sanofi-Synthélabo acquired Aventis; the combined group was called Sanofi-Aventis and returned to the shorter name Sanofi in 2011. Its shares are listed on Euronext Paris, where it is part of the CAC 40 index, and on Nasdaq in the US.
Sanofi develops and makes prescription medicines and vaccines. Its main areas include immunology, rare diseases, neurology, oncology, diabetes and vaccines, the latter produced by its Sanofi Pasteur unit. One of its best-known medicines is dupilumab (Dupixent), developed together with Regeneron.
The company has grown through major acquisitions: Genzyme, a US specialist in rare diseases, in 2011, and Bioverativ and Ablynx in 2018. In 2024 Sanofi agreed to transfer a 50% controlling stake in its consumer health business, Opella, to the investment firm CD&R, while keeping a significant shareholding.
Rilutek (riluzole) was developed by Rhône-Poulenc Rorer, one of the companies that formed Aventis. In 1995 it became the first medicine approved in the US for amyotrophic lateral sclerosis (ALS).
Unifarm carries Sanofi's neurology medicine Rilutek 50 (riluzole), used to treat amyotrophic lateral sclerosis.